Vicks in Japan
This article was originally published in The Tan Sheet
Executive Summary
P&G transfers Vicks medicated cough drop business in Japan to Taisho Pharmaceutical in deal announced May 14. Under agreement, Taisho obtains perpetual license rights to trademark, formula of Vicks Medicated Drops, as well as rights to all product sales; P&G will continue as contract manufacturer "for the foreseeable future," Taisho says. Firm also becomes exclusive sales agent of VicksVapoRub in Japan, although P&G will continue to manufacture the product. P&G says deal is part of its strategic decision to invest in larger markets; aside from Japan, Vicks Medicated Drops are only sold in India, Indonesia, Singapore and are not among top-selling Vicks offerings...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.